Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Eupraxia Reports Strong Q1 2026 Results and Positive RESOLVE Trial Data

Eupraxia Pharmaceuticals Inc. announced its financial results for the first quarter of 2026, reporting a net loss of $12.7 million, an increase from $6.8 million in Q1 2025, primarily due to higher research and development costs. The company highlighted robust clinical data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE), showing near-complete improvement on biopsy and positive nine-month tissue health and symptom data in the highest dose cohort. Eupraxia also completed a public offering, raising approximately $63.2 million, which has bolstered its cash and short-term investments to $138.9 million as of March 31, 2026. These funds are expected to provide a cash runway into the second half of 2028, supporting the continued development of EP-104GI and expansion into new gastrointestinal indications.

• Eupraxia Pharmaceuticals reported significant clinical advancements for its lead candidate, EP-104GI, in the ongoing Phase 1b/2a RESOLVE trial for Eosinophilic Esophagitis (EoE). Data from the highest dose cohort demonstrated near-complete improvement on biopsy, along with positive six-month symptom data and nine-month tissue health and symptom data. These results reinforce the potential of EP-104GI as an important new treatment option for EoE, leveraging the company's proprietary Diffusphere™ technology for targeted drug delivery.
• The company significantly strengthened its financial position by completing a public offering that generated approximately $63.2 million in gross proceeds. This financing, combined with existing cash and short-term investments, resulted in a total of $138.9 million in cash and equivalents as of March 31, 2026. This capital infusion is projected to fund Eupraxia's operations and clinical development programs, including EP-104GI, into the second half of 2028, extending beyond anticipated key catalysts.
• Eupraxia's strategic focus involves leveraging its proprietary Diffusphere™ technology, designed for local, controlled drug delivery, to address therapeutic areas with high unmet medical need. The company plans to accelerate additional clinical programs for EP-104GI in new gastrointestinal indications, capitalizing on the technology's ability to provide hyper-targeted delivery to diseased areas over an extended period without typical systemic exposure. This approach aims to improve the safety, tolerability, efficacy, and duration of effect of both existing and novel drugs.

EP-104GI Shows Robust Response in RESOLVE Trial for EoE

The Cendakimab Phase 3 Trial (NCT04753697) evaluated this high-affinity monoclonal antibody targeting IL-13 in 430 patients with EoE aged 12-75 years. The study compared two dosing regimens of cendakimab 360 mg (once weekly for 48 weeks or once weekly for 24 weeks then every other week) against placebo. At week 24, cendakimab demonstrated statistically significant improvements in dysphagia days (reduction of -6.1 vs -4.2 days for placebo, P<0.001) and histologic response, with 28.6% achieving peak esophageal eosinophil counts ≤6 per high-power field versus 2.2% with placebo (P<0.001). Endoscopic severity also improved significantly, and efficacy was maintained through week 48. Safety analysis showed adverse events in 83.8-84.6% of cendakimab-treated patients compared to 73.4% with placebo, though the adverse-event profile was not dose-limiting.

Dupilumab Phase III trials included the LIBERTY EoE TREET Study (NCT03633617) in adults and adolescents ≥12 years, and the EoE KIDS Study (NCT04394351) in children aged 1-12 years. This fully human monoclonal antibody blocking IL-4α receptor demonstrated improved outcomes versus placebo across all age groups when administered as 300 mg weekly subcutaneous injections (or weight-tiered equivalent dosing in children). Population pharmacokinetics modeling identified alternative regimens for specific weight ranges and validated the approach through 52 weeks of treatment. Dupilumab has received regulatory approval for EoE in patients ≥1 year and ≥15 kg, with adverse events remaining comparable to placebo in clinical trials.

A comprehensive meta-analysis of budesonide encompassing 11 randomized controlled trials with 1,089 participants confirmed this topical corticosteroid's efficacy in EoE management. The analysis demonstrated significant improvements in histologic remission (RR: 26.85; 95% CI: 13.72-52.56), peak eosinophil count reduction, clinical response rates, and dysphagia symptom scores. Safety outcomes showed overall adverse events comparable to placebo, though infections were more frequent with budesonide (RR: 2.14; 95% CI: 1.20-3.80), primarily localized oropharyngeal candidiasis rarely requiring treatment discontinuation. Notably, transient cortisol suppression was observed, warranting long-term adrenal monitoring, while fibrosis scores showed no significant improvement.

EP-104GI's Unique Delivery and RESOLVE Trial Design

The key eosinophilic esophagitis trials demonstrate a consistent evolution toward standardized endpoints and patient populations, with recent Phase 3 studies establishing clear efficacy benchmarks. These trials span multiple therapeutic classes and include both adult and pediatric populations, with treatment durations ranging from 8 weeks to 52 weeks. The studies predominantly employ randomized, double-blind, placebo-controlled designs with histologic and symptomatic co-primary endpoints.

Why New EoE Treatments Like EP-104GI Are Needed

Current treatment approaches for eosinophilic esophagitis face significant challenges that limit optimal patient outcomes. The therapeutic landscape is characterized by regulatory gaps, limited evidence base, and suboptimal efficacy of existing interventions. These limitations underscore the critical need for novel treatment approaches with improved efficacy and safety profiles.

• Regulatory and evidence gaps: No FDA-approved therapy existed for eosinophilic esophagitis in the United States until recently, and current first-line treatment recommendations are based on relatively few studies employing various doses and formulations of swallowed topical steroids

• Limited maintenance efficacy: Low-dose budesonide (0.25 mg twice daily) showed limited efficacy in maintaining remission, with esophageal eosinophil load increasing from 0.4 to 31.8 eosinophils/high-power field over 50 weeks and similar symptom score development compared to placebo

• Lack of comparative effectiveness data: A paucity of direct comparisons exists among available pharmacologic treatments for EoE, and the best long-term management strategy for this chronic inflammatory disease has not been determined

• Immunotherapy complications: Eosinophilic esophagitis is a known complication of oral immunotherapy for food allergy, with desensitization effects being temporary and safety concerns remaining a major limitation

• Adjunctive therapy limitations: Esophageal dilations serve only as adjunct therapy for fibrostenotic EoE without treating the underlying inflammation, and dupilumab is unlikely to replace PPIs or STSs as first-line therapy except in highly specific circumstances

• Pediatric research deficits: Several emerging biologics targeting inflammatory pathways are under investigation in adults, but studies are lacking in much of the pediatric population, limiting treatment options for younger patients

• Biomarker-driven treatment needs: Patients with positive IgG4 histological staining exhibit significantly higher rates of endoscopic edema and greater need for second-line treatment, highlighting the need for biomarkers to identify patient subsets better suited for specific treatments

Sustained-Release Fluticasone: A New Horizon for EoE Management

Eupraxia Pharmaceuticals' recent financial update, coupled with compelling Phase 1b/2a data for EP-104GI in Eosinophilic Esophagitis (EoE), signals a company poised for significant impact. EoE is a chronic, immune-mediated inflammatory disorder characterized by eosinophilic infiltration, leading to symptoms like dysphagia and food impaction. Current therapeutic mainstays include swallowed topical corticosteroids (TCS) such as fluticasone propionate and budesonide, which are effective in reducing eosinophil counts and improving mucosal integrity. However, these treatments often require frequent administration, and concerns persist regarding their long-term safety, particularly in children, and their ability to reverse underlying esophageal remodeling.

EP-104GI, a novel sustained-release formulation of fluticasone propionate, appears to address some of these limitations. The reported "near-complete improvement on biopsy" and "positive nine-month tissue health and symptom data" from the RESOLVE trial suggest a potential for prolonged efficacy, which could significantly enhance patient adherence and quality of life. This sustained-release technology is a core competency for Eupraxia, as evidenced by its EP-104IAR program for osteoarthritis, which also utilizes a long-acting fluticasone propionate formulation with minimal systemic effects. The successful public offering, providing a robust cash runway into 2028, further strengthens the company's ability to advance EP-104GI through pivotal trials and explore its application in other gastrointestinal inflammatory conditions.

However, the path forward is not without its challenges. The impressive early-phase data for EP-104GI must be rigorously validated in larger, well-controlled Phase 3 studies. Replicating "near-complete improvement" and demonstrating statistically significant symptomatic relief will be critical, especially given that some prior steroid trials showed strong histological but less pronounced symptomatic benefits. Furthermore, as a corticosteroid, EP-104GI will need to establish a long-term safety profile that minimizes systemic side effects and addresses concerns about esophageal remodeling. The competitive landscape, featuring established proton pump inhibitors and emerging biologics, necessitates a clear differentiation strategy for EP-104GI to carve out its market niche. The coming years will reveal if this innovative formulation can truly transform EoE management.